Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Cisio De Oliveira Brandao, Sandra Lewis, Darcie Sandschafer & Jeffrey Crawford. (2023) Two decades of pegfilgrastim: what have we learned? Where do we go from here?. Current Medical Research and Opinion 39:5, pages 707-718.
Read now
Read now
Edouard Alphandéry, Pierre Grand-Dewyse, Raphael Lefèvre, Chalani Mandawala & Mickael Durand-Dubief. (2015) Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Review of Anticancer Therapy 15:10, pages 1233-1255.
Read now
Read now
Sunday Ocheni, Tatjana Zabelina, Ulrike Bacher, Francis Ayuk, Axel Zander & Nicolaus Kröger. (2009) Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors. Leukemia & Lymphoma 50:4, pages 612-618.
Read now
Read now
Alissa Huston & Gary H Lyman. (2007) Agents under investigation for the treatment and prevention of neutropenia. Expert Opinion on Investigational Drugs 16:11, pages 1831-1840.
Read now
Read now
Articles from other publishers (28)
Zongzhi Jiang, Ziyi Wang, Xiaojing Wei & Xue-Fan Yu. (2022) Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets. Frontiers in Immunology 13.
Crossref
Crossref
Tao Xie, Hui Fang, Weiming Ouyang, Phillip Angart, Meng-Jung Chiang, Ashwinkumar A. Bhirde, Faruk Sheikh, Patrick Lynch, Ankit B. Shah, Sharadrao M. Patil, Kang Chen, Meiyu Shen, Cyrus Agarabi, Raymond P. Donnelly, Kurt Brorson, Sarah J. Schrieber, Kristina E. Howard, Sarah M. Rogstad & David M. Frucht. (2020) The ELISA Detectability and Potency of Pegfilgrastim Decrease in Physiological Conditions: Key Roles for Aggregation and Individual Variability. Scientific Reports 10:1.
Crossref
Crossref
Eiseki Usami, Michio Kimura, Mina Iwai, Makiko Go, Hiroki Asano, Shoya Takenaka, Shino Adachi & Tomoaki Yoshimura. (2018) The incidence and timing of leukocyte overshoot after pegfilgrastim administration. Journal of Oncology Pharmacy Practice 25:4, pages 869-874.
Crossref
Crossref
A. S. Simbirtsev. (2019) Immunopharmacological aspects of the cytokine system. Bulletin of Siberian Medicine 18:1, pages 84-95.
Crossref
Crossref
Jean-Charles Ryff & Sidney Pestka. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
619
643
.
Mark P Rubinstein, Mohamed L Salem, Andrew L Doedens, Caitlin J Moore, Cody Chiuzan, Guillermo L Rivell, David J Cole & Ananda W Goldrath. (2013) G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Karen Tomic, Stacey Long, Xiaoyan Li, An-Chen Fu, Tzy-Chyi Yu & Richard Barron. (2013) A retrospective study of patients’ out-of-pocket costs for granulocyte colony-stimulating factors. Journal of Oncology Pharmacy Practice 19:4, pages 328-337.
Crossref
Crossref
Jean-Charles Ryff & Sidney Pestka. 2013. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
413
437
.
Ofer YanayDavid C. DaleWilliam R.A. Osborne. (2012) Repeated Lentivirus-Mediated Granulocyte Colony-Stimulating Factor Administration to Treat Canine Cyclic Neutropenia. Human Gene Therapy 23:11, pages 1136-1143.
Crossref
Crossref
Tian-Lu Cheng, Kuo-Hsiang Chuang, Bing-Mae Chen & Steve R. Roffler. (2012) Analytical Measurement of PEGylated Molecules. Bioconjugate Chemistry 23:5, pages 881-899.
Crossref
Crossref
Stephen J. Szilvassy. 2012. Twenty Years of G-CSF. Twenty Years of G-CSF
293
317
.
Eveliina Pollari, Ekaterina Savchenko, Merja Jaronen, Katja Kanninen, Tarja Malm, Sara Wojciechowski, Toni Ahtoniemi, Gundars Goldsteins, Raisa Giniatullina, Rashid Giniatullin, Jari Koistinaho & Johanna Magga. (2011) Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation 8:1.
Crossref
Crossref
Yu-Cheng Su, Bing-Mae Chen, Kuo-Hsiang Chuang, Tian-Lu Cheng & Steve R. Roffler. (2010) Sensitive Quantification of PEGylated Compounds by Second-Generation Anti-Poly(ethylene glycol) Monoclonal Antibodies. Bioconjugate Chemistry 21:7, pages 1264-1270.
Crossref
Crossref
Gary H. Lyman. 2011. Hematopoietic Growth Factors in Oncology. Hematopoietic Growth Factors in Oncology
109
125
.
Lazzaro Repetto. (2009) Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey. Critical Reviews in Oncology/Hematology 72:2, pages 170-179.
Crossref
Crossref
Christine Herbst, Frauke Naumann, Eva-Brigitta Kruse, Ina Monsef, Julia Bohlius, Holger Schulz & Andreas Engert. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Lew M. IacovelliBrandy L. Persson. (2008) Management of Chemotherapy-Induced Neutropenia: Opportunities for Pharmacist Involvement. Hospital Pharmacy 43:6, pages 472-484.
Crossref
Crossref
C Herbst, F Naumann, E Kruse, I Knauel, H Schulz, J Bohlius & A Engert. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Ercole Brusamolino. (2008) Managing the myelotoxicity of CHOP chemotherapy. European Journal of Cancer Supplements 6:2, pages 31-36.
Crossref
Crossref
David Cameron & Matti Aapro. (2008) Managing myelotoxicities of breast cancer chemotherapies: what is the role for G-CSF?. European Journal of Cancer Supplements 6:2, pages 17-23.
Crossref
Crossref
Bjoern-N Heydrich, Robert Schoch, Heinz-August Horst & Michael Kneba. (2007) Dramatic hyperleukocytosis after treatment of myelodysplastic syndrome with pegfilgrastim and darbepoetin-alfa. Annals of Hematology 87:1, pages 77-78.
Crossref
Crossref
Pellegrino Musto, Potito Rosario Scalzulli, Elisabetta Terruzzi, Fausto Rossini, Pasquale Iacopino, Giuseppe Messina, Roberto Guariglia, Giuseppe Pietrantuono, Oreste Villani, Fiorella D’Auria, Antonietta Falcone, Grazia Sanpaolo, Maria Rosa Valvano, Enrico Maria Pogliani & Fortunato Morabito. (2007) Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: Case-control study in patients with multiple myeloma and review of the literature. Leukemia Research 31:11, pages 1487-1493.
Crossref
Crossref
Ronald L Snyder & Delevan J Stringham. (2016) Pegfilgrastim-Induced Hyperleukocytosis. Annals of Pharmacotherapy 41:9, pages 1524-1530.
Crossref
Crossref
Gary H Lyman & Michelle Shayne. (2007) Granulocyte colony-stimulating factors: finding the right indication. Current Opinion in Oncology 19:4, pages 299-307.
Crossref
Crossref
Nicolas André, Maria El Kababri, Pourroy Bertrand, Angelique Rome, Carole Coze, Jean Claude Gentet & Jean Louis Bernard. (2007) Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anti-Cancer Drugs 18:3, pages 277-281.
Crossref
Crossref
Anas Younes, Luis Fayad, Jorge Romaguera, Barbara Pro, Andre Goy & Michael Wang. (2006) Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. European Journal of Cancer 42:17, pages 2976-2981.
Crossref
Crossref
Lorenzo Livi, Fabiola Paiar, Roberto Santini, Carla De Luca Cardillo, Alessandra Galardi, Dora Di Cosmo, Simona Borghesi, Benedetta Agresti, Fabiano Nosi, Sergio Gavilli & Gian Paolo Biti. (2006) Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer. Anti-Cancer Drugs 17:9, pages 1081-1085.
Crossref
Crossref
Gary Walsh & Roy Jefferis. (2006) Post-translational modifications in the context of therapeutic proteins. Nature Biotechnology 24:10, pages 1241-1252.
Crossref
Crossref